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ABSTRACT 
Screening asymptomatic people with a resting electrocardiogram (ECG) has been 
theorised to detect latent cardiovascular disease. However, resting ECG screening is 
not recommended for numerous populations, such as asymptomatic middle-aged 
(sedentary) people, as it is not sufficiently sensitive to detect coronary artery 
disease. While the issues raised in this article are largely common to all screening 
programs, this review focuses on two distinct programs: (1) screening elite athletes 
for conditions associated with sudden cardiac death (SCD); and (2) screening people 
aged ≥65 years for atrial fibrillation (AF). These two settings have recently gained 
attention for their promise and concerns regarding prevention of SCD and stroke, 
respectively. If screening is done, it must be done well. Organisations conducting 
screening must consider a range of legal, ethical and logistical responsibilities which 
arise from the beginning to end of the process. This includes consideration of who to 
screen, timing of screening, whether it is mandatory, consent issues, and auditing 
systems to ensure quality control. Good infrastructure for interpretation of ECG 
results according to expert guidelines, and follow-up testing for abnormal screening 
results, including a pathway to treatment, are essential. Finally, there may be 
significant implications for those diagnosed with cardiac disease, including 
insurance, employment, the ability to play sport and mental health issues. There are 
several legal risks, and the best protective measures are good communication 
systems, thorough clinical records, careful handling of eligibility questions for those 
diagnosed, and reference to expert guidelines as the standard of care. 
Keywords: legal, ethical, screening, athletes, atrial fibrillation, sudden death 
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INTRODUCTION 
Many electrocardiogram (ECG) screening programs exist internationally, usually with 
the key aim of using a resting ECG to screen asymptomatic people for potentially 
life-threatening cardiac diseases (Table 1). These programs have been trialled in 
broad age groups: young athletes (including elite athletes), middle-aged people (both 
sedentary and athletes) and older people (often aged ≥65 years). The rationale for 
screening athletes is that intense exercise represents a trigger for cardiac 
arrhythmias, meaning athletes may be at greater risk of sudden cardiac death 
(SCD). Screening has also been investigated in older populations at risk of thrombo-
embolic complications of atrial fibrillation (AF). The rationale is that oral 
anticoagulants (OAC) have demonstrated efficacy in preventing stroke in individuals 
with AF, even if the person is asymptomatic. The groups for which screening is 
recommended vary, e.g., the European Association of Preventive Cardiology (EAPC) 
recommends screening (including a resting ECG) asymptomatic middle-aged/senior 
individuals engaging in high-intensity sport,1 which is not generally recommended by 
other experts.2, 3 In Italy4 and Israel,5 ECG screening of all young athletes (of any 
level) is mandated, whereas in most other countries ECG screening of athletes is 
restricted to the elite level. We note that ECG screening in asymptomatic middle-
aged sedentary people is not recommended by any leading bodies.2, 3 
While the issues raised are largely common to all screening programs, this review 
focuses on two distinct programs: (1) screening elite athletes for conditions 
associated with SCD; and (2) screening for AF in people aged ≥65 years. These 
programs were selected as they represent two of the largest, and increasingly 
common, cardiac screening programs. As with all discussions on screening, these 
issues relate to testing asymptomatic people. Those with suspicious symptoms 
and/or significant family history should seek specialist advice.6  
 (i) Rationale for screening elite athletes  
SCD is a tragic outcome for athletes and their families. Although relatively rare, SCD 
is the leading cause of death for people playing sport.7 In the US, over 90 young 
athletes die suddenly each year (about 2 per 100,000 athletes per year).7 This rate is 
2.5-fold higher than that of the age-matched non-athlete population.8 The risk of 
SCD, or sudden cardiac arrest, (SCA/D) varies according to age, gender, ethnicity, 
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sport and competitive level.9  In Australia, SCD in the young (aged 1-35 years) 
occurs in 1.3 per 100,000 people per year and approximately 15% occur either 
during exercise (11%) or immediately after exercise (4%).10 Competitive sport may 
be a significant risk factor for young people with genetic heart diseases, such as 
hypertrophic cardiomyopathy (HCM), arrhythmogenic cardiomyopathy, familial long 
QT syndrome, and catecholaminergic polymorphic ventricular tachycardia, that can 
lead to SCD without the athlete having any symptoms beforehand.  
There is strong debate about whether screening programs are worthwhile in terms of 
preventing SCD in young people.11 Data from Italy, where cardiac screening of 
athletes is mandated by law, is often cited as persuasive evidence in favour 
screening: this study compared the incidence of SCD in the years before and during 
screening, showing a 90% reduction in the screened population.4 However, this 
success has not been mirrored in Israel, nor in various US programs.12 
A detailed review by the American Medical Society for Sports Medicine (AMSSM) 
suggests the decision about screening should depend on the baseline risk of SCD in 
the relevant population, and the availability of required cardiology resources and 
infrastructure to properly conduct such a program.9 Many major organisations and 
sports governing bodies now recommend cardiac screening of athletes. For many, 
there is a “strong pragmatic argument” to screen as “a well-resourced professional 
organisation [has] a perceived need to…have taken every possible step to reduce 
this risk”.6 For professional athletes who are employees, there is also a work, health 
and safety argument in favour of screening as athletes are required to push their 
bodies in the course of employment, and any cardiac abnormalities raising the risk of 
SCD should be identified, as vigorous exercise can be a trigger. There is a 
substantial cost in running a screening program, with one model estimating a 20-
year screening program of young US athletes would cost US$10million per life 
saved.13 In the UK, the Football Association (FA) reported a cost of US$342 per 
athlete for initial screening (including ECG and echocardiogram) and US$102,782 
per case of disease associated with SCD.14 Another UK program reported a cost of 
US$87 per athlete screened (including ECG and taking into account follow-up 
costs).15 
 (ii) Rationale for AF screening  
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AF is the most common cardiac arrhythmia, and the prevalence rises steeply with 
age.16 Estimates are that 25% of middle-aged adults in Europe and the US will 
develop AF in their lifetime.17 About 1.4% of the population aged ≥65 have 
undiagnosed AF, which is commonly asymptomatic.16 Left untreated, AF results in 
an up to fivefold increased risk of stroke.16  
Screening for AF in people aged ≥65 years is now recommended by numerous 
guidelines and expert consensus.16-19 Data are lacking on the outcomes of AF 
screening (e.g. reduction of stroke), and guidelines are based on the premise that 
the prognosis of screen-detected AF is similar to AF detected incidentally and will 
respond similarly to OAC.20 Most guidelines recommend opportunistic screening, by 
pulse palpation or single-lead ECG. For those at high risk of stroke (CHA2DS2-
VASc≥2 in males or ≥3 in females), treatment with OAC can reduce stroke risk by 
64% compared to control.17, 21  Economic assessments have generally found AF 
screening programs to be cost-effective.16  
 
KEY ISSUES IN CARDIAC SCREENING 
Once an organisation has decided to conduct a screening program, there are 
ensuing legal, ethical and logistical responsibilities. The primary point is that if 
screening is to be done, it must be done well.22, 23 Several papers helpfully contribute 
to these issues,24-27 but most emphasise the doctor’s role (rather than the 
organisation’s role), and focus on the end part of the process: treating individuals 
who have been diagnosed and/or preventing litigation. These aspects are important, 
but relate to a minority of patients and a small part of the process. There are many 
legal, ethical and logistical issues involved in designing/running an ECG screening 
program, from the beginning to the end of the process (Figure 1).  
Eligibility  
The first question is: who is eligible for screening? A key ethical issue with screening 
is that the condition, if found, must be serious enough to outweigh the negatives of 
screening (time, false positives, etc). Ideally, screening should be offered to 
sufficiently at-risk people. According to Bayes’ theorem, the chance of a positive 
being a true positive is proportional to the baseline incidence in the population being 
screened. 
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In sport, some groups are much higher risk e.g. the annual risk of SCD for 
African/Afro-Caribbean (“black”) male basketballers is 1 in 4400,28 and may be 
prioritised. Conversely, black athletes have demonstrably higher proportions of 
pathological ECG abnormalities, confounding interpretation. Athlete screening often 
commences at 16 years, given that ECG variability under this age is more common – 
the “juvenile ECG pattern”.29 Arguably, athlete screening should be done early 
enough that the person has flexibility choose another career if a serious cardiac 
condition is detected. For AF, most guidelines use an age cut-off.17, 18  
Method of screening & frequency 
Another important consideration is the method and frequency of screening, with a 
focus on compliance. Considerations include whether an opt-in or opt-out model 
works best, and/or whether systematic or opportunistic screening is more 
appropriate.  
When screening athletes, it is important to consider whether an opt-in or opt-out 
model is preferable. Opt-out may produce a higher rate of compliance, though 
athletes should be given sufficient opportunity to make an informed decision about 
whether to participate. However, whether a program should be mandatory may be 
less important than developing a ‘best practice’ program: something that varies 
according to the population and resources available.23 
There has been debate about whether an ECG is required for athlete screening. 
While the ESC recommends an ECG,30 the AHA recommends a history and physical 
but not ECG.11 Evidence now suggests an ECG substantially improves sensitivity 
and specificity of screening compared with a clinical examination alone.6, 14 There 
are no clear recommendations about frequency of screening, but it appears a single 
screen at age 16 may not be sufficient,14 and every 2 years (under age 21), and 
every 5 years thereafter, may be more appropriate. This approach has recently been 
adopted by the FA.31 Refinements to athlete ECG interpretation criteria (the Seattle 
criteria32 and now the International criteria29), have substantially improved diagnostic 
yield. 
Most AF screening guidelines now recommending opportunistic, rather than 
systematic, screening.20 As we have previously argued, the focus should be more on 
screening a higher proportion of the at-risk population in order to increase the 
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effectiveness of stroke prevention.20 In terms of frequency, most guidelines 
recommend single time-point screening, as opposed to continuous ECG monitoring 
over a longer period which may detect “brief episodes of AF of questionable clinical 
significance”.20 As we have noted, this will present challenges with the rise of 
wearable technology, e.g. smartwatches with AF-detection algorithms and ECG 
capability (Applewatch4), often worn by younger people at lower risk of stroke.20 
Evidence is lacking as to the ideal frequency, but current suggestions are for annual 
screening.16  
 
Timing  
Screening is often performed as an adjunct task, at a time that suits the 
doctor/practice or sporting organisation. However, practices/organisations must be 
aware of the potential implications and ensure there is time to obtain informed 
consent, and to organise follow-up if required, taking into account the person’s work, 
travel or playing commitments. The best model would vary according to 
circumstances, but in general it is preferable to give people advance notice, and to 
screen athletes in the off-season or, in our opinion, at least 10 working days before 
competing to ensure there is sufficient time to complete follow-up if required. 
 
Consent issues  
In general, patients must give informed consent before undergoing screening. This 
requires an understanding of the benefits and harms,33 the accuracy of the test, 
risks, and the implications of an abnormal result.34 Patient information materials 
often over-emphasise benefits and underplay harms and uncertainties.35   
Issues of capacity may also arise with younger or elderly people, who may be 
considered vulnerable populations. Children aged under 18 years can be vulnerable 
due a lack of capacity to make decisions, and power inequalities with adults.36 Older 
patients can also be vulnerable, especially those with multiple chronic conditions.37 
These issues must be considered carefully to ensure the person is capable of 
understanding the process and implications of screening. People under 18 who are 
considered ‘mature minors’ may have capacity to consent to screening, although for 
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younger people (e.g. age 15), it may be prudent to obtain parental consent. Similar 
considerations may apply to elderly people, e.g. with dementia. 
Second, the issue of consenting to ‘half a screen’ can be a problem. This occurs 
when a person consents to the initial test, but refuses (either overtly or covertly) to 
get follow-up as recommended. Importantly, there must be a system to identify those 
who have not completed required follow-up and a policy for what to do in this 
scenario. Defining what is a reasonable level of follow-up depends on the 
circumstances, but should be well documented. Completing the screening process 
can be more easily mandated for athletes who are employees, and elderly people 
who are regular patients of a practice. 
 
Communication of results and pathway to treatment  
All results must be reviewed, filed, communicated and followed up if required.  ECG 
review must be completed by someone with relevant expertise. Athlete ECGs, must 
be reviewed by someone with specific expertise in best-practice interpretation 
guidelines29 to reduce false positives. For AF, many single-lead devices have an 
automated algorithm for interpretation but those with a diagnosis of ‘possible AF’ 
must be verified, and those with an ‘unclassified’ diagnosis must also be reviewed. 
All 12-lead ECG automated diagnoses also require review. Other work up, including 
a review of the CHA2DS2-VASc stroke risk scores, and discussion of benefits and 
risks of treatment, should be done in accordance with guidelines.17 
A well-established pathway to follow-up testing and treatment for anyone with a 
verified abnormal test result is crucial.16 In a sports setting, the required 
infrastructure for screening includes sufficient cardiology resources to ensure ECGs 
are interpreted by someone with relevant expertise and that abnormal screening 
results are followed up.9 The ‘pathway to treatment’ should include consideration of 
logistics, whether playing/training can continue before the test is complete, and cover 
players who are visiting temporarily. In Izidor v Knight38, a college basketball player 
was screened and ultimately diagnosed with HCM. However, the clearance form was 
signed before the follow-up testing and diagnosis was complete. The athlete 
continued to play but died of SCD 6 weeks later. This case shows the importance of 
adhering to the screening policy and completing testing before providing clearance.  
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Communication and filing are crucial. Sub-optimal communication between patients 
and doctors is a major risk factor for negligence cases, and therefore a key area for 
prevention.39  An abnormal result that is not read and/or followed up is risky. Even 
the best system will miss things occasionally, but this must be minimised. 
Abnormal screening results and follow-up  
A substantial number of people will require follow-up tests, and the person 
conducting screening must be prepared to counsel patients with an abnormal result. 
Approximately 5% of athletes screened will require extra testing.40 Due to electrical 
and structural changes in the heart resulting from high level training, athlete ECG 
interpretation guidelines have been continuously refined and improved,40 with the 
International Criteria(2017)29 now the gold standard. This has substantially reduced 
false positives, with one study showing the proportion of abnormal ECGs falling from 
21.8% (2010 ESC recommendations) to 4.3% (Refined criteria).15 Ultimately 0.3% of 
athletes in this study were diagnosed with a serious cardiac condition, and all these 
ECGs were abnormal irrespective of the interpretation criteria used.15 A reduced 
false positive rate decreases screening cost,15 and improves identification of 
pathology.40 Anxiety is a key harm and can be reduced with timely communication 
and completion of follow-up tests.20, 41 Interestingly, a study of screening in US 
college athletes found ECG screening did not cause undue anxiety for the majority 
(including those with false positive results).41  
For AF, approximately 12% of patients screened with a single-lead ECG will have an 
abnormal result (e.g. an automated result of possible AF or ‘unclassified’).42 
‘Unclassified’ results may be caused by conditions such as sinus 
tachycardia/bradycardia, left or right bundle branch block or multiple ectopic beats. 
Additional testing will include echocardiography.17 Potentially unnecessary additional 
testing may result from an AF diagnosis and is a significant concern of the US 
Preventive Services Task Force.43 
Importantly, there may be cases of ‘false reassurance’ as even the best program will 
miss some cases.14 For athletes, only 60% of the conditions associated with SCD 
are visible on ECG.44  The dynamic nature of electrical cardiac problems means they 
can be missed, e.g. a single time-point screen may miss paroxysmal AF, leading to 
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intermittent ECG protocols.16 Thus, people undergoing screening must be informed 
of these limitations, and encouraged to report any symptoms in future. 
 
Cardiac emergency response  
The importance of having a documented and well-practised action plan in place for 
cardiac emergencies, ideally including access to automated external defibrillators 
(AEDs), cannot be overstated.9 Early recognition of SCA or stroke is crucial, and 
training relevant staff to identify symptoms can provide benefits well beyond the 
screened cohort. In sport, any non-traumatic collapse should be treated as cardiac 
until proven otherwise. For the elderly, educating practice staff, doctors and patients 
to be aware of stroke symptoms is key in promoting early access to treatment. 
Program evaluation 
All screening programs should be evaluated regularly to assess efficacy, benefits 
and harms. Reviews should also consider of any new scientific evidence that should 
be reflected in the program and/or current care, and should ideally include updates 
on education regarding cardiac emergency response (e.g. resuscitation and stroke 
recognition). 
 
Issues for those diagnosed with a cardiac condition 
For those diagnosed with a cardiac condition, there may be important implications for 
insurance, work, sport and mental health. As with all medico-legal issues, insurance 
rules vary by jurisdiction. Once diagnosed, any pre-existing heart condition can have 
implications for acquiring new insurance such as travel, health or life insurance. 
Premiums may be higher, exclusions added or cover refused. Some jurisdictions 
have protections for certain types of insurance e.g. Australian private health 
insurance is community-rated [Private Health Insurance Act 2007(Cth)], meaning 
everyone pays the same premium for the same product regardless of health status 
or claims history. 
Genetic testing is important, especially for young people diagnosed before they have 
life insurance. In general, when applying for insurance, a person must disclose 
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relevant health information, including genetic tests. Some jurisdictions, offer little 
protection, e.g. in Australia, life insurers can use genetic test results to raise 
premiums, impose conditions or refuse insurance altogether if based on actuarial or 
statistical data [s46 Disability Discrimination Act 1992(Cth)], and can even ask 
whether an applicant is considering or awaiting results,45 but cannot ask an applicant 
to have a genetic test. Other jurisdictions, including the UK, Canada and many 
European countries have banned insurers from using genetic test results.46   
Issues may arise regarding employment and driving, e.g. in the UK, AF is a notifiable 
condition and may prevent a person driving a bus/lorry.47 Many countries regulate 
the use of genetic tests in employment, however it is unclear how this would apply to 
an athlete who is an employee (especially if disqualification is recommended and/or 
for an athlete who is, e.g., genotype-positive/phenotype-negative for HCM).24 
Importantly, there are substantial psychological implications for athletes disqualified 
from sport. As documented by Asif et al, these athletes may experience significant 
psychological distress and should be monitored and offered support.48  
Eligibility and disqualification from sport  
A central issue for those diagnosed with a serious cardiac condition is eligibility to 
play sport. Historically, a paternalistic approach was favoured, with athletes 
‘disqualified’ from competitive sport. While the ESC guidelines(2005)49 remain 
generally more restrictive, a  more permissive approach with a ‘shared decision-
making model’ is included in the ACC guidelines(2015).50 The ACC guidelines are 
more recent, and take into account research developments in risk stratification. 
However, there are many areas which require further research and most guidelines 
are mainly based on expert consensus.27 Similarly, a model of ‘empowerment’ has 
been proposed, which allows athletes to choose the extent to which they participate 
in the eligibility decision.27 The ethical implications of disqualification, particularly with 
screen-detected conditions in asymptomatic athletes, have been discussed 
comprehensively in a review which proposes an individualised approach with 
‘collaborative decision-making’.24  
Realistically, the physician’s risk profile is as important as the athlete’s. Legal and 
ethical responsibility is fundamental, and a doctor is less likely to ‘forbid’ participation 
if they unlikely to be blamed/liable. One option for sports is to have a group of 
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experts to assist with decisions (with the player’s consent), as in the FA.14 There is 
also a question of what amount of cardiac risk an athlete is able to consent to in an 
organised setting, especially for minors, and where the athlete is an employee, 
general work, health and safety obligations apply to the employer. Sporting 
organisations also face substantial reputational (and other) risk if an athlete suffers 
SCA/D on television.  
 
Litigation risks 
Litigation is highly stressful and public, even for people/organisations ultimately 
vindicated. Laws are specific to each jurisdiction but the general legal duty is to 
provide best medical care available, based on the current state of scientific 
knowledge.22 The standard of care is often established by asking what the 
hypothetical ‘reasonable’ physician, exercising due care and skill, would have done 
in those circumstances? Expert guidelines may be persuasive evidence of the 
standard of care.51 The importance of having thorough, contemporaneous clinical 
notes, documenting any restrictions on activity, cannot be overstated.51 Specific 
areas of risk include: 
• Poor communication: Good communication may not be sufficient to prevent all 
litigation, but is a strong protective measure. 
• Detecting disease, but not treating it: if a condition is detected, a treatment 
decision must be made in a timely fashion. If an untreated patient suffers a 
stroke, it may constitute a breach of duty, as stroke may be a reasonably 
foreseeable outcome.52 One legal website specifically advertises services for AF 
patients who may have experienced negligence in OAC prescription.53 
• Clearing someone with disease is an obvious risk. ECGs, and any follow-up 
tests, must be completed and interpreted with due care and skill.26 To the extent 
possible, guidelines should be followed.54 
• Exclusion from sport: guidelines are not consistent, but generally exclusion 
decisions need to be reasonable, well explained and based on a thorough 
scientific process.55 There are several US cases where players sued 
unsuccessfully to challenge exclusion from sport, e.g. in Larkin v Archdiocese of 
Cincinnati56 the Court held a football player with HCM could be excluded from 
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competing, even though he was willing to sign a waiver. Team physicians have a 
complex ‘dual loyalty’ between the athlete and the team’s needs.54 Ideally, 
decisions about eligibility should be decided by an expert panel (with the player’s 
consent), and/or follow guidelines. 
• Waivers: Beware. Courts often question waivers, which do not remove the 
doctor’s legal obligation to conform to applicable standards of good medical 
practice.25, 51 Waivers between an adult professional athlete and a team 
physician may be enforceable, particularly where another specialist has cleared 
the player,51 but this raises a ‘red flag’ and potential ‘doctor shopping’ to get the 
desired opinion.26 
• Any major adverse event such as a stroke or SCA/D, especially in public and/or 
if it appears preventable, represents a major risk. Good documentation and 
notes, including informed consent and discussion of risks of non-compliance with 
treatment or activity restrictions, are important.25 In Gathers v Loyola-Marymount 
University,57 a basketball player was prescribed a beta-blocker for ventricular 
tachycardia but his dose was reduced to improve performance. Shortly 
afterwards, he suffered a SCD on television. His family sued the doctor and 
university for US$32.5 million, although the case settled.  
 
CONCLUSIONS 
Many organisations, such as general practices and sports, are now conducting 
cardiac screening programs using a resting ECG. Any screening program involves 
some potential downsides, including anxiety, time, additional testing and cost. 
Screening is often performed as an adjunct task and therefore, very good systems 
are needed for communication, filing, and ensuring a pathway to treatment. 
If screening of asymptomatic people is performed, it must be done well. Once an 
organisation has committed to screening, there are a range of legal, ethical and 
logistical responsibilities that must be addressed. This includes consideration of who 
to screen, timing and frequency, whether screening is mandatory, auditing systems 
and consent issues. Systems for communicating results and facilitating follow-up 
testing for abnormal results, including a pathway to treatment, are essential. Finally, 
there may be significant implications for those diagnosed with cardiac disease, 
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including insurance, employment, mental health and the ability to play sport. There 
are several legal risks, and the best protective measures physicians can take are to 
communicate well, keep thorough clinical records, (potentially) to involve a group of 
experts in eligibility questions, and to follow expert guidelines as the standard of 
care. 
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Table 1: Resting ECG screening of asymptomatic individuals 
Group Screening 
Population 
Groups/organisations in 
favour 
Arguments 
against 
Summary 
All young 
people 
Cardiac 
conditions 
associated 
with SCD 
 
Cardiac Risk in the Young 
(CRY), UK 
 
Mandated by law for 
young athletes (broadly 
defined) in Italy,4 Israel5 
* Expensive 
* Large number of 
false positives 
* Lack of evidence 
in support 
Not recommended in 
most countries 
Young elite 
athletes 
(age 16-35 
years) 
Vast majority of major 
sporting organisations 
and guidelines, e.g.:  
* ESC30  
* AHA (history and 
physical, not ECG)11 
* International Olympic 
Committee 
* American Medical 
Society for Sports 
Medicine (AMSSM)9 
* Australasian College of 
Sport and Exercise 
Physicians (ACSEP)58 
* FIFA 
* World Rugby  
*Expensive 
* Need 
randomised trial 
evidence of 
benefit 
Consider, if sufficient 
infrastructure 
available to support 
program 
Middle-aged 
sedentary 
people 
(aged 35-64 
years) 
Acquired 
cardiac 
disease, 
arrhythmias 
Some clinics * Cannot detect 
coronary artery 
disease in 
absence of prior 
infarction 
* Generally low 
risk group for AF 
Not recommended2, 3 
Middle-
aged/senior 
people 
engaging in 
physical 
activity 
Acquired 
cardiac 
disease, 
arrhythmias 
*EAPC,1 based on self-
assessment of individual’s 
cardiac risk and the 
intensity of exercise 
* Individual risk 
assessment may 
be inaccurate  
* Cannot detect 
coronary artery 
disease in 
absence of prior 
infarction 
 
Consider for higher 
risk individuals 
undertaking intense 
exercise 
Elderly (age 
≥65 years) 
AF Many guidelines 
recommend AF 
screening, including with 
a single-lead ECG, e.g.:  
* ESC17  
* AF-SCREEN16 
* Heart Foundation of 
Australia18  
* European Heart Rhythm 
Association (EHRA), 
Heart Rhythm Society 
(HRS) et al19 
* Insufficient 
evidence of 
reduction of risk of 
screen-detected 
AF 
Consider, if sufficient 
infrastructure 
available to support 
program 
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FIGURE LEGENDS 
 
Figure 1: Timeline of issues related to ECG screening 
ECG, electrocardiogram; SCA, sudden cardiac arrest 
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